Latest Publication: Read our teams’ latest paper in Antibiotics, showing reduced nephrotoxicity of a novel formulation of polymyxin B compared to the clinical formulation using a validated primary human proximal tubule cell model.
Emanuela’s extensive career brings a wealth of experience in marketing in the life science and biotechnology industry and a track record of senior leadership roles at some of the…
Read update 9th November, 2023Terry’s career in the life science industry spans more than 30 years. He was the CEO of Cambridge based Horizon Discovery Plc, a public company listed on the UK…
Read updateCan you tell us a little bit about your professional journey and how you made the transition to industry? I have an undergraduate Degree in biomedical science and also completed…
Read update 9th November, 2023Terry’s career in the life science industry spans more than 30 years. He was the CEO of Cambridge based Horizon Discovery Plc, a public company listed on the UK…
Read update 12th October, 2023We recently expanded our imaging capability with the purchase of an ImageXpress Pico high content imaging (HCI) system from Molecular Devices. Since then, our technical teams have been busy…
Read update 29th August, 2023CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…
Read update 28th July, 2023About the conference: MPS summit The MPS summit is a small but buzzing conference, where scientists from the pharma industry, academia and microchip manufacturers gather to discuss the latest advances…
Read update 30th June, 2023About the conference : ILD Summit The ILD Summit is a niche industry dedicated conference focussed on advancing therapies for progressive fibrosing interstitial lung diseases (ILD). This year’s conference was the…
Read update